Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma

Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extramedullary disease from myeloma patients without s...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-09, Vol.10 (9), p.e0137294-e0137294
Main Authors: Besse, Lenka, Sedlarikova, Lenka, Kryukov, Fedor, Nekvindova, Jana, Radova, Lenka, Slaby, Ondrej, Kuglik, Petr, Almasi, Martina, Penka, Miroslav, Krejci, Marta, Adam, Zdenek, Pour, Ludek, Sevcikova, Sabina, Hajek, Roman
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bioinformatics
Biology
Biomarkers
Biomarkers, Tumor - analysis
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Bone marrow
Bone Marrow - pathology
Cancer
Care and treatment
Diagnosis
Female
Gene expression
Gene Expression Regulation, Neoplastic
Genetic aspects
Genetic markers
Hematology
Humans
Infiltration
Internal medicine
Leukemia
Life assessment
Lymphoma
Male
Medical diagnosis
Medical prognosis
Medicine
Metastases
MicroRNA
MicroRNAs
MicroRNAs - analysis
MicroRNAs - blood
MicroRNAs - genetics
Middle Aged
miRNA
Multiple myeloma
Multiple Myeloma - blood
Multiple Myeloma - diagnosis
Multiple Myeloma - genetics
Multiple Myeloma - pathology
Pathogenesis
Patients
Physiological aspects
Physiology
Plasma cells
Plasma Cells - pathology
Prognosis
Ribonucleic acid
RNA
Sensitivity
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extramedullary disease from myeloma patients without such manifestation and from healthy donors. MicroRNA-130a was identified by TaqMan Low Density Arrays and verified by quantitative PCR on 144 serum samples (59 multiple myeloma, 55 myeloma with extramedullary disease, 30 healthy donors) in test and validation cohorts as being down-regulated in myeloma patients with extramedullary disease. Circulating microRNA-130a distinguished myeloma patients with extramedullary disease from healthy donors with specificity of 90.0% and sensitivity of 77.1%, patients with extramedullary disease from newly diagnosed multiple myeloma patients with specificity of 77.1% and sensitivity of 34.3% in the test cohort and with specificity of 91.7% and sensitivity of 30.0% in the validation cohort of patients. Circulating microRNA-130a in patients with extramedullary myeloma was associated with bone marrow plasma cells infiltration. Further, microRNA-130a was decreased in bone marrow plasma cells obtained from patients with extramedullary myeloma in comparison to bone marrow plasma cells of myeloma patients without such manifestation, but it was increased in tumor site plasma cells of patients with extramedullary disease compared to bone marrow plasma cells of such patients (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0137294